This comprehensive report provides an in-depth analysis of the global female contraception market, projecting its growth trajectory through 2032. The study examines key market dynamics, including trends in product types such as birth control pills, injections, and IUDs, as well as applications across various age demographics. By evaluating regional landscapes in the Americas, APAC, Europe, and MEA, the report highlights emerging opportunities and competitive strategies employed by major industry players like Merck & Co. and Bayer AG.

Market Overview

The global Female Contraception market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate.

Regional Market Projections

• United States: The market for Female Contraception in the United States is estimated to increase from 2025 through 2032, maintaining a consistent compound annual growth rate.
• China: The market for Female Contraception in China is estimated to increase from 2025 through 2032, maintaining a consistent compound annual growth rate.
• Europe: The market for Female Contraception in Europe is estimated to increase from 2025 through 2032, maintaining a consistent compound annual growth rate.

Report Scope and Methodology

Produced by LP Information, Inc. (LPI), the “Female Contraception Industry Forecast” examines historical sales and reviews total global Female Contraception sales in 2025. The report provides a comprehensive analysis by region and market sector of projected Female Contraception sales for the period of 2026 through 2032.

With sales broken down by region, market sector, and sub-sector, this report offers a detailed analysis in US$ millions of the global Female Contraception industry. This insight report provides a comprehensive analysis of the global landscape and highlights key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

Furthermore, the report analyzes the strategies of leading global companies, focusing on their Female Contraception portfolios and capabilities, market entry strategies, market positions, and geographic footprints to better understand their unique positions in an accelerating global market.

This study evaluates the key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Female Contraception market.

The report presents a comprehensive overview, market shares, and growth opportunities categorized by product type, application, key manufacturers, and key regions and countries.

Market Segmentation

By Type

• Birth Control Pills
• Contraceptive Injection
• Contraceptive Patch
• IUDs
• Female Condom
• Others

By Application

• 18-25 Years Old
• 26-35 Years Old
• 36-45 Years Old
• >45 Years Old
• Others

By Region

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Global key Female Contraception players include Amgen Inc., Ansell Ltd., Exeltis USA Inc., Medisafe Distribution Inc., and Merck & Co. Inc. In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

The following companies have been profiled based on primary expert input and analysis of company coverage, product portfolio, and market penetration:

• Amgen Inc.
• Ansell Ltd.
• Exeltis USA Inc.
• Medisafe Distribution Inc.
• Merck & Co. Inc.
• Mylan NV
• Pfizer Inc.
• Piramal Enterprises Ltd.
• Afaxys Pharma LLC
• Agile Therapeutics Inc.
• Bayer AG
• CooperSurgical Inc.
• Cupid Ltd.
• Johnson & Johnson
• Mayer Laboratories Inc.
• Teva Pharmaceutical Industries Ltd
• Actavis, Inc.
• Gedeon Richter
• Novo Nordisk A/S
• ZiZhu
• Baijingyu
• Huazhong
• Sine
• AbbVie
• Church & Dwight
• Reckitt
• TherapeuticsMD

Key Questions Addressed

• What is the 10-year outlook for the global Female Contraception market?
• What factors are driving Female Contraception market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Female Contraception market opportunities vary by end market size?
• How does Female Contraception break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Female Contraception Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Female Contraception by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Female Contraception by Country/Region, 2021, 2025 & 2032

  • 2.2 Female Contraception Segment by Type

    • 2.2.1 Birth Control Pills

    • 2.2.2 Contraceptive Injection

    • 2.2.3 Contraceptive Patch

    • 2.2.4 IUDs

    • 2.2.5 Female Condom

    • 2.2.6 Others

    • 2.2.7 Female Contraception Sales by Type

      • 2.2.7.1 Global Female Contraception Sales Market Share by Type (2021-2026)
      • 2.2.7.2 Global Female Contraception Revenue and Market Share by Type (2021-2026)
      • 2.2.7.3 Global Female Contraception Sale Price by Type (2021-2026)

  • 2.3 Female Contraception Segment by Application

    • 2.3.1 18-25 Years Old

    • 2.3.2 26-35 Years Old

    • 2.3.3 36-45 Years Old

    • 2.3.4 ＞45 Years Old

    • 2.3.5 Others

    • 2.3.6 Female Contraception Sales by Application

      • 2.3.6.1 Global Female Contraception Sale Market Share by Application (2021-2026)
      • 2.3.6.2 Global Female Contraception Revenue and Market Share by Application (2021-2026)
      • 2.3.6.3 Global Female Contraception Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Female Contraception Breakdown Data by Company

    • 3.1.1 Global Female Contraception Annual Sales by Company (2021-2026)

    • 3.1.2 Global Female Contraception Sales Market Share by Company (2021-2026)

  • 3.2 Global Female Contraception Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Female Contraception Revenue by Company (2021-2026)

    • 3.2.2 Global Female Contraception Revenue Market Share by Company (2021-2026)

  • 3.3 Global Female Contraception Sale Price by Company

  • 3.4 Key Manufacturers Female Contraception Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Female Contraception Product Location Distribution

    • 3.4.2 Players Female Contraception Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Female Contraception by Geographic Region

  • 4.1 World Historic Female Contraception Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Female Contraception Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Female Contraception Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Female Contraception Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Female Contraception Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Female Contraception Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Female Contraception Sales Growth

  • 4.4 APAC Female Contraception Sales Growth

  • 4.5 Europe Female Contraception Sales Growth

  • 4.6 Middle East & Africa Female Contraception Sales Growth

• 5 Americas

  • 5.1 Americas Female Contraception Sales by Country

    • 5.1.1 Americas Female Contraception Sales by Country (2021-2026)

    • 5.1.2 Americas Female Contraception Revenue by Country (2021-2026)

  • 5.2 Americas Female Contraception Sales by Type (2021-2026)

  • 5.3 Americas Female Contraception Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Female Contraception Sales by Region

    • 6.1.1 APAC Female Contraception Sales by Region (2021-2026)

    • 6.1.2 APAC Female Contraception Revenue by Region (2021-2026)

  • 6.2 APAC Female Contraception Sales by Type (2021-2026)

  • 6.3 APAC Female Contraception Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Female Contraception by Country

    • 7.1.1 Europe Female Contraception Sales by Country (2021-2026)

    • 7.1.2 Europe Female Contraception Revenue by Country (2021-2026)

  • 7.2 Europe Female Contraception Sales by Type (2021-2026)

  • 7.3 Europe Female Contraception Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Female Contraception by Country

    • 8.1.1 Middle East & Africa Female Contraception Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Female Contraception Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Female Contraception Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Female Contraception Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Female Contraception

  • 10.3 Manufacturing Process Analysis of Female Contraception

  • 10.4 Industry Chain Structure of Female Contraception

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Female Contraception Distributors

  • 11.3 Female Contraception Customer

• 12 World Forecast Review for Female Contraception by Geographic Region

  • 12.1 Global Female Contraception Market Size Forecast by Region

    • 12.1.1 Global Female Contraception Forecast by Region (2027-2032)

    • 12.1.2 Global Female Contraception Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Female Contraception Forecast by Type (2027-2032)

  • 12.7 Global Female Contraception Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Amgen Inc.

    • 13.1.1 Amgen Inc. Company Information

    • 13.1.2 Amgen Inc. Female Contraception Product Portfolios and Specifications

    • 13.1.3 Amgen Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Amgen Inc. Main Business Overview

    • 13.1.5 Amgen Inc. Latest Developments

  • 13.2 Ansell Ltd.

    • 13.2.1 Ansell Ltd. Company Information

    • 13.2.2 Ansell Ltd. Female Contraception Product Portfolios and Specifications

    • 13.2.3 Ansell Ltd. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Ansell Ltd. Main Business Overview

    • 13.2.5 Ansell Ltd. Latest Developments

  • 13.3 Exeltis USA Inc.

    • 13.3.1 Exeltis USA Inc. Company Information

    • 13.3.2 Exeltis USA Inc. Female Contraception Product Portfolios and Specifications

    • 13.3.3 Exeltis USA Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Exeltis USA Inc. Main Business Overview

    • 13.3.5 Exeltis USA Inc. Latest Developments

  • 13.4 Medisafe Distribution Inc.

    • 13.4.1 Medisafe Distribution Inc. Company Information

    • 13.4.2 Medisafe Distribution Inc. Female Contraception Product Portfolios and Specifications

    • 13.4.3 Medisafe Distribution Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Medisafe Distribution Inc. Main Business Overview

    • 13.4.5 Medisafe Distribution Inc. Latest Developments

  • 13.5 Merck & Co. Inc.

    • 13.5.1 Merck & Co. Inc. Company Information

    • 13.5.2 Merck & Co. Inc. Female Contraception Product Portfolios and Specifications

    • 13.5.3 Merck & Co. Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Merck & Co. Inc. Main Business Overview

    • 13.5.5 Merck & Co. Inc. Latest Developments

  • 13.6 Mylan NV

    • 13.6.1 Mylan NV Company Information

    • 13.6.2 Mylan NV Female Contraception Product Portfolios and Specifications

    • 13.6.3 Mylan NV Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Mylan NV Main Business Overview

    • 13.6.5 Mylan NV Latest Developments

  • 13.7 Pfizer Inc.

    • 13.7.1 Pfizer Inc. Company Information

    • 13.7.2 Pfizer Inc. Female Contraception Product Portfolios and Specifications

    • 13.7.3 Pfizer Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Pfizer Inc. Main Business Overview

    • 13.7.5 Pfizer Inc. Latest Developments

  • 13.8 Piramal Enterprises Ltd.

    • 13.8.1 Piramal Enterprises Ltd. Company Information

    • 13.8.2 Piramal Enterprises Ltd. Female Contraception Product Portfolios and Specifications

    • 13.8.3 Piramal Enterprises Ltd. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Piramal Enterprises Ltd. Main Business Overview

    • 13.8.5 Piramal Enterprises Ltd. Latest Developments

  • 13.9 Afaxys Pharma LLC

    • 13.9.1 Afaxys Pharma LLC Company Information

    • 13.9.2 Afaxys Pharma LLC Female Contraception Product Portfolios and Specifications

    • 13.9.3 Afaxys Pharma LLC Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Afaxys Pharma LLC Main Business Overview

    • 13.9.5 Afaxys Pharma LLC Latest Developments

  • 13.10 Agile Therapeutics Inc.

    • 13.10.1 Agile Therapeutics Inc. Company Information

    • 13.10.2 Agile Therapeutics Inc. Female Contraception Product Portfolios and Specifications

    • 13.10.3 Agile Therapeutics Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 Agile Therapeutics Inc. Main Business Overview

    • 13.10.5 Agile Therapeutics Inc. Latest Developments

  • 13.11 Bayer AG

    • 13.11.1 Bayer AG Company Information

    • 13.11.2 Bayer AG Female Contraception Product Portfolios and Specifications

    • 13.11.3 Bayer AG Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 Bayer AG Main Business Overview

    • 13.11.5 Bayer AG Latest Developments

  • 13.12 CooperSurgical Inc.

    • 13.12.1 CooperSurgical Inc. Company Information

    • 13.12.2 CooperSurgical Inc. Female Contraception Product Portfolios and Specifications

    • 13.12.3 CooperSurgical Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.12.4 CooperSurgical Inc. Main Business Overview

    • 13.12.5 CooperSurgical Inc. Latest Developments

  • 13.13 Cupid Ltd.

    • 13.13.1 Cupid Ltd. Company Information

    • 13.13.2 Cupid Ltd. Female Contraception Product Portfolios and Specifications

    • 13.13.3 Cupid Ltd. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.13.4 Cupid Ltd. Main Business Overview

    • 13.13.5 Cupid Ltd. Latest Developments

  • 13.14 Johnson & Johnson

    • 13.14.1 Johnson & Johnson Company Information

    • 13.14.2 Johnson & Johnson Female Contraception Product Portfolios and Specifications

    • 13.14.3 Johnson & Johnson Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.14.4 Johnson & Johnson Main Business Overview

    • 13.14.5 Johnson & Johnson Latest Developments

  • 13.15 Mayer Laboratories Inc.

    • 13.15.1 Mayer Laboratories Inc. Company Information

    • 13.15.2 Mayer Laboratories Inc. Female Contraception Product Portfolios and Specifications

    • 13.15.3 Mayer Laboratories Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.15.4 Mayer Laboratories Inc. Main Business Overview

    • 13.15.5 Mayer Laboratories Inc. Latest Developments

  • 13.16 Teva Pharmaceutical Industries Ltd

    • 13.16.1 Teva Pharmaceutical Industries Ltd Company Information

    • 13.16.2 Teva Pharmaceutical Industries Ltd Female Contraception Product Portfolios and Specifications

    • 13.16.3 Teva Pharmaceutical Industries Ltd Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.16.4 Teva Pharmaceutical Industries Ltd Main Business Overview

    • 13.16.5 Teva Pharmaceutical Industries Ltd Latest Developments

  • 13.17 Actavis, Inc.

    • 13.17.1 Actavis, Inc. Company Information

    • 13.17.2 Actavis, Inc. Female Contraception Product Portfolios and Specifications

    • 13.17.3 Actavis, Inc. Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.17.4 Actavis, Inc. Main Business Overview

    • 13.17.5 Actavis, Inc. Latest Developments

  • 13.18 Gedeon Richter

    • 13.18.1 Gedeon Richter Company Information

    • 13.18.2 Gedeon Richter Female Contraception Product Portfolios and Specifications

    • 13.18.3 Gedeon Richter Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.18.4 Gedeon Richter Main Business Overview

    • 13.18.5 Gedeon Richter Latest Developments

  • 13.19 Novo Nordisk A/S

    • 13.19.1 Novo Nordisk A/S Company Information

    • 13.19.2 Novo Nordisk A/S Female Contraception Product Portfolios and Specifications

    • 13.19.3 Novo Nordisk A/S Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.19.4 Novo Nordisk A/S Main Business Overview

    • 13.19.5 Novo Nordisk A/S Latest Developments

  • 13.20 ZiZhu

    • 13.20.1 ZiZhu Company Information

    • 13.20.2 ZiZhu Female Contraception Product Portfolios and Specifications

    • 13.20.3 ZiZhu Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.20.4 ZiZhu Main Business Overview

    • 13.20.5 ZiZhu Latest Developments

  • 13.21 Baijingyu

    • 13.21.1 Baijingyu Company Information

    • 13.21.2 Baijingyu Female Contraception Product Portfolios and Specifications

    • 13.21.3 Baijingyu Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.21.4 Baijingyu Main Business Overview

    • 13.21.5 Baijingyu Latest Developments

  • 13.22 Huazhong

    • 13.22.1 Huazhong Company Information

    • 13.22.2 Huazhong Female Contraception Product Portfolios and Specifications

    • 13.22.3 Huazhong Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.22.4 Huazhong Main Business Overview

    • 13.22.5 Huazhong Latest Developments

  • 13.23 Sine

    • 13.23.1 Sine Company Information

    • 13.23.2 Sine Female Contraception Product Portfolios and Specifications

    • 13.23.3 Sine Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.23.4 Sine Main Business Overview

    • 13.23.5 Sine Latest Developments

  • 13.24 AbbVie

    • 13.24.1 AbbVie Company Information

    • 13.24.2 AbbVie Female Contraception Product Portfolios and Specifications

    • 13.24.3 AbbVie Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.24.4 AbbVie Main Business Overview

    • 13.24.5 AbbVie Latest Developments

  • 13.25 Church & Dwight

    • 13.25.1 Church & Dwight Company Information

    • 13.25.2 Church & Dwight Female Contraception Product Portfolios and Specifications

    • 13.25.3 Church & Dwight Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.25.4 Church & Dwight Main Business Overview

    • 13.25.5 Church & Dwight Latest Developments

  • 13.26 Reckitt

    • 13.26.1 Reckitt Company Information

    • 13.26.2 Reckitt Female Contraception Product Portfolios and Specifications

    • 13.26.3 Reckitt Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.26.4 Reckitt Main Business Overview

    • 13.26.5 Reckitt Latest Developments

  • 13.27 TherapeuticsMD

    • 13.27.1 TherapeuticsMD Company Information

    • 13.27.2 TherapeuticsMD Female Contraception Product Portfolios and Specifications

    • 13.27.3 TherapeuticsMD Female Contraception Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.27.4 TherapeuticsMD Main Business Overview

    • 13.27.5 TherapeuticsMD Latest Developments

• 14 Research Findings and Conclusion